Tìm theo
CRA-024781
Thuốc Gốc
Small Molecule
CRA-024781 is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. It is being developed by Celera Genomics for the treatment of cancer and currently under Phase I of clinical trail.
Cơ Chế Tác Dụng : CRA-024781 is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. It is being developed by Celera Genomics for the treatment of cancer and currently under Phase I of clinical trail. CRA-024781 is a novel histone deacetylase (HDAC) inhibitor. HDAC inhibitors target HDAC enzymes and inhibit the proliferation of cancer cells and induce cancer cell death, or apoptosis (1). Histone deacetylation is carried out by a family of related HDAC enzymes. Inhibition of these enzymes causes changes to chromatin structure and to gene expression patterns, which results in the inhibition of proliferation of cancer cells, and induction of apoptosis.
Chỉ Định : Investigated for use/treatment in cancer/tumors (unspecified).
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05921
... loading
... loading